4
Changes in Ownership
CORCEPT THERAPEUTICS INC Filed Acc 0001193125-26-274224
Chief Financial Officer sold 40,000 shares at an average $81.15 ($3,245,900)
- Chief Financial Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Mokari Atabak · Chief Financial Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-06-15 | Exercise or conversion : show line 1 in the form 10b5-1 | +40,000 | $19.26 | $770,400 | 56,130 | D |
| 2026-06-15 | Sale : show line 2 in the form 10b5-1 | −9,434 | $80.02 | $754,924 | 46,696 | D |
| 2026-06-15 | Sale : show line 3 in the form 10b5-1 | −11,081 | $80.94 | $896,923 | 35,615 | D |
| 2026-06-15 | Sale : show line 4 in the form 10b5-1 | −19,483 | $81.81 | $1,593,889 | 16,132 | D |
| 2026-06-15 | Sale : show line 5 in the form 10b5-1 | −2 | $82.45 | $165 | 16,130 | D |
| Open-market sales · 40,000 sh · avg $81.15 · $3,245,900 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-06-15 | Exercise or conversion : show line 6 in the form 10b5-1 Stock option (right to buy) | −40,000 | 20,000 | D |
Loading xslF345X06/ownership.xml…